A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren ' s Syndrome

Conditions: Sjogren ' s Syndrome Interventions: Drug: HZN-1116; Drug: Placebo Sponsors: Horizon Therapeutics Ireland DAC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials